Spruce Biosciences (Nasdaq: SPRB) is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases with significant unmet medical needs.

Alessa Therapeutics, Inc. is a clinical-stage biotech company focused on the development and commercialization of selective and sustained localized drug delivery for early interception of cancer and other diseases.

Americares is a global non-profit organization focused on health and development that responds to individuals affected by poverty, disaster, or crisis. The organization addresses poverty, disasters, or crises with medicine, medical supplies, and health programs.

Plexium Inc. is a clinical-stage Targeted Protein Degradation (TPD) company seeking to discover monovalent direct degraders and molecular glues that address difficult-to-drug targets for the treatment of cancer and neurological diseases. The company's proprietary drug discovery platform is designed to identify novel small molecules that induce selective degradation of pathogenic proteins through E3 ligase mediated proteasomal degradation.

Spearheaded the execution of Astellas’ Corporate Strategic Plan and the company's efforts to enhance internal and external innovation. Led Business Development, Alliance Management, Advanced Informatics & Analytics, Intellectual Property, Patient Centricity, Information Systems, iota Biosciences, Rx+ Business Accelerator, and the Transformation Office.

Led Astellas Pharma's operations across the United States, headquartered in Northbrook, IL, with over $4.5 Billion in annual revenues. Member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

The Roche Leadership Development Program (LDP) identifies and develops high-potential Roche executives for leadership positions through rotational assignments in a variety of key roles globally.